Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Interpace Biosciences, Inc. (IDXG)
Price$1.41Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.7M | $46.9M | $40.0M | $31.8M | $33.1M | $32.4M | $24.2M | $21.9M | $15.9M | $13.1M | $9.4M | $119.9M | $146.5M | $126.9M | $157.3M | $134.6M |
| Gross profit | $24.1M | $29.9M | $25.1M | $18.2M | $18.8M | $10.7M | $8.3M | $11.7M | $8.5M | $6.4M | $2.5M | $206,000 | $23.5M | $26.9M | $32.5M | $26.6M |
| Gross margin | 62.31% | 63.77% | 62.58% | 57.26% | 56.78% | 33.10% | 34.40% | 53.43% | 53.71% | 49.25% | 26.74% | 0.17% | 16.04% | 21.17% | 20.64% | 19.73% |
| Research & development | $642,000 | $676,000 | $636,000 | $703,000 | $1.5M | $2.8M | $2.8M | $2.1M | $1.5M | $1.6M | $2.3M | $255,000 | — | — | — | — |
| Operating expenses | $20.0M | $21.8M | $21.1M | $21.8M | $25.1M | $36.8M | $34.8M | $24.3M | $14.8M | $12.9M | $42.9M | $18.0M | $24.9M | $52.1M | $37.2M | $33.5M |
| Operating income | $4.1M | $8.1M | $4.0M | −$3.6M | −$6.3M | −$26.1M | −$26.4M | −$12.6M | −$6.3M | −$6.4M | −$40.4M | −$17.8M | −$1.4M | −$25.2M | −$4.7M | −$6.9M |
| Operating margin | 10.55% | 17.28% | 9.88% | −11.36% | −19.13% | −80.46% | −109.15% | −57.70% | −39.59% | −49.23% | −428.41% | −14.86% | −0.98% | −19.88% | −2.99% | −5.13% |
| EBITDA | $4.5M | $8.4M | $5.0M | −$1.1M | −$962,000 | −$20.6M | −$21.9M | −$8.8M | −$2.6M | −$2.0M | −$35.4M | −$15.4M | −$12,000 | −$23.2M | −$1.7M | −$5.1M |
| EBITDA margin | 11.64% | 17.92% | 12.44% | −3.32% | −2.90% | −63.48% | −90.47% | −40.34% | −16.37% | −14.97% | −375.08% | −12.87% | −0.01% | −18.28% | −1.05% | −3.77% |
| Net income | $24.6M | $6.7M | $2.0M | −$22.0M | −$14.9M | −$26.5M | −$26.7M | −$12.7M | $12.6M | −$22.0M | −$13.6M | −$16.8M | −$4.6M | −$25.5M | −$11.9M | −$6.8M |
| Net profit margin | 63.46% | 14.28% | 4.88% | −68.97% | −45.12% | −81.64% | −110.40% | −58.02% | 78.96% | −168.15% | −144.43% | −13.98% | −3.12% | −20.12% | −7.57% | −5.06% |
| Basic EPSper basic share | $5.55 | $1.42 | $0.45 | -$5.18 | -$3.61 | -$7.32 | -$7.25 | -$4.52 | -$7.96 | -$120.90 | -$87.95 | -$108.00 | -$31.00 | -$175.00 | -$83.00 | -$48.00 |
| Diluted EPSper diluted share | $0.89 | $0.40 | $0.45 | -$5.18 | -$3.61 | -$7.32 | -$7.25 | -$4.52 | -$7.96 | -$120.90 | -$87.95 | -$108.00 | -$31.00 | -$175.00 | -$83.00 | -$48.00 |
Owners
Reported shareholders